UnitedHealth Group is realigning its strategy by exiting some Medicare Advantage plans and focusing on value-based care, which helps reduce medical costs and improve profit margins. The company plans further price increases and aims to expand its Medicare Advantage Star ratings, supporting revenue growth through 2027 and 2028. Currently trading near historical valuation levels, UNH offers strong upside potential despite risks like momentum fatigue and upcoming Medicare payment rate changes. Its growing free cash flow, disciplined capital returns, and solid balance sheet make it a compelling buy for long-term investors.
UnitedHealth's strategic shifts come as the stock trades near its 52-week high, signaling sustained investor interest. On Pluang, UNH is priced at USD 413.37, up 0.73% for the day as of Oct 28, 2026 21:01 WIB, with a market cap of $368.36 billion. Despite a majority of order activity leaning towards selling at 63%, the stock maintains a dividend yield of 2.26% and a typical hold time of 98 days, reflecting steady engagement from investors.
Halper Sadeh LLC is investigating whether certain UnitedHealth Group officers and directors violated their fiduciary duties to shareholders. Long-term shareholders may seek reforms, financial incentives, or other relief if wrongdoing is found. The fi...
Thermo Fisher Scientific reported 5% organic growth, surpassing consensus by 2 percentage points, prompting management to raise its full-year growth forecast. Mettler-Toledo's local-currency sales grew 6%, exceeding its previous 3% guidance. TEVA als...
